These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10049294)

  • 1. Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients.
    Wintergerst U; Rolinski B; Sölder B; Bogner JR; Wolf E; Jäger H; Roscher AA; Belohradsky BH
    Antimicrob Agents Chemother; 1999 Mar; 43(3):699-701. PubMed ID: 10049294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study.
    Wang Y; Livingston E; Patil S; McKinney RE; Bardeguez AD; Gandia J; O'Sullivan MJ; Clax P; Huang S; Unadkat JD
    J Infect Dis; 1999 Nov; 180(5):1536-41. PubMed ID: 10515813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.
    Balis FM; Pizzo PA; Butler KM; Hawkins ME; Brouwers P; Husson RN; Jacobsen F; Blaney SM; Gress J; Jarosinski P
    J Infect Dis; 1992 Jan; 165(1):99-104. PubMed ID: 1727902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
    Rongkavilit C; Thaithumyanon P; Chuenyam T; Damle BD; Limpongsanurak S; Boonrod C; Srigritsanapol A; Hassink EA; Hoetelmans RM; Cooper DA; Lange JM; Ruxrungtham K; Phanuphak P
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3585-90. PubMed ID: 11709344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.
    Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Urien S; Foulongne V; Van De Perre P; Tréluyer JM; Msellati P
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4399-406. PubMed ID: 19581461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.
    Stevens RC; Rodman JH; Yong FH; Carey V; Knupp CA; Frenkel LM
    AIDS Res Hum Retroviruses; 2000 Mar; 16(5):415-21. PubMed ID: 10772527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
    Gibb D; Barry M; Ormesher S; Nokes L; Seefried M; Giaquinto C; Back D
    Br J Clin Pharmacol; 1995 May; 39(5):527-30. PubMed ID: 7669489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral absorption of anti-aids nucleoside analogues: 3. Regional absorption and in vivo permeability of 2',3'-dideoxyinosine in an intestinal-vascular access port (IVAP) dog model.
    Sinko PJ; Sutyak JP; Leesman GD; Hu P; Makhey VD; Yu H; Smith CL
    Biopharm Drug Dispos; 1997 Nov; 18(8):697-710. PubMed ID: 9373726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients.
    Wintergerst U; Rolinski B; Bogner JR; Notheis G; Goebel FD; Roscher AA; Belohradsky BH
    Antimicrob Agents Chemother; 1997 May; 41(5):1143-5. PubMed ID: 9145885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).
    Molina JM; Peytavin G; Perusat S; Lascoux-Combes C; Sereni D; Rozenbaum W; Chene G
    HIV Med; 2004 Mar; 5(2):99-104. PubMed ID: 15012649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus.
    Knupp CA; Brater DC; Relue J; Barbhaiya RH
    J Clin Pharmacol; 1993 Oct; 33(10):912-7. PubMed ID: 8227460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.
    Li RC; Narang PK; Sahai J; Cameron W; Bianchine JR
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1566-70. PubMed ID: 9210686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection.
    Mueller BU; Pizzo PA; Farley M; Husson RN; Goldsmith J; Kovacs A; Woods L; Ono J; Church JA; Brouwers P
    J Pediatr; 1994 Jul; 125(1):142-6. PubMed ID: 8021765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients.
    Cato A; Qian J; Hsu A; Vomvouras S; Piergies AA; Leonard J; Granneman R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):466-72. PubMed ID: 9715843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.